Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,286 | 0,288 | 17:20 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.04. | Theraclion Announces Financial Results 2024 and Reviews Progress | 315 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces... ► Artikel lesen | |
26.03. | Theraclion Completes Its Previous Financing Round With an Additional Convertible Bonds Issuance | 428 | Business Wire | Issuance of warrants for bonds convertible into shares, in accordance with Theraclion's commitment, to investors who have requested them, for a maximum amount of 580,000 euros. 290,000... ► Artikel lesen | |
20.02. | Theraclion Secures Financing From Its Historical Shareholders Through a Convertible Bond Loan | 564 | Business Wire | Reserved issuance of warrants for convertible bonds based on a fixed price per share of 0.20 euros (without discount), for a maximum amount of €6 million, benefiting Furui and Unigestion, the... ► Artikel lesen | |
11.02. | Theraclion Announces Treatment of First Patients With New SONOVEIN 'SpeedPulse' Feature Accelerating Treatment | 391 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces... ► Artikel lesen | |
07.02. | Theraclion: Publication of Adjusted Accounts for the First Half of 2024 | 493 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment... ► Artikel lesen | |
06.01. | Theraclion Reviews Its 2024 Achievements | 320 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment... ► Artikel lesen | |
30.10.24 | Theraclion Announces Major Advances and Reports First-Half Financial Results | 491 | Business Wire | On the strength of its progress on its 2023 and 2024 priorities (access to the US market, R&D and China), Theraclion is planning its commercial ramp-up for 2025 and 2026. Pivotal study for... ► Artikel lesen | |
06.09.24 | Theraclion Confirms Strong Mid-Year Achievements | 456 | Business Wire | Main focus: Access to the U.S. market, R&D and China. Key achievements in H1 2024: FDA pivotal study: treatments completed in June on schedule
Promising R&D progress in product features... ► Artikel lesen | |
THERACLION Aktie jetzt für 0€ handeln | |||||
24.06.24 | SONOVEIN FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on Schedule | 674 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE) innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy... ► Artikel lesen | |
06.06.24 | Theraclion: SONOVEIN Highlighted in Top Medical Conferences and Scientific Journal | 576 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
GERRESHEIMER | 47,680 | -2,97 % | Allianz, Amazon, Deutsche Konsum, Gerresheimer, Hensoldt, Moderna - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
INMODE | 12,500 | -0,28 % | InMode Ltd.: InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025 | YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent... ► Artikel lesen | |
MCKESSON | 627,00 | +0,80 % | Dividendenbekanntmachungen (02.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCOR SA FR0000120404 - 1,26 EUR ASSOCIATED BANC-CORP US0454871056 0,23 USD 0,2026 EUR ATOUR LIFESTYLE HOLDINGS LTD ADR US04965M1062 0... ► Artikel lesen | |
HCA HEALTHCARE | 332,50 | -0,42 % | Is HCA Healthcare Stock Outperforming the Nasdaq? | ||
LIMES SCHLOSSKLINIKEN | 330,00 | 0,00 % | Limes Schlosskliniken will 2025 klar wachsen | 2024 kommt Limes Schlosskliniken wie im Vorjahr auf Gesamterträge von 38,0 Millionen Euro. Schon vor wenigen Wochen hatte Limes-Chef Gert Frank auf einer Konferenz von Oddo BHF in Frankfurt deutlich... ► Artikel lesen | |
BEYOND AIR | 0,161 | 0,00 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
HEALTHCARE SERVICES GROUP | 12,200 | -0,81 % | HCSG Reports Q4 2024 Results | BENSALEM, Pa.--(BUSINESS WIRE)--Healthcare Services Group, Inc. (NASDAQ:HCSG) today reported results for the three months ended December 31, 2024.
Ted Wahl, Chief Executive Officer, stated, "2024... ► Artikel lesen | |
INTERPACE BIOSCIENCES | 0,650 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
ADDUS HOMECARE | 96,50 | 0,00 % | Breaking Down Addus HomeCare: 6 Analysts Share Their Views | ||
IVF HARTMANN | 148,00 | -1,33 % | IVF Hartmann 2024 mit deutlich mehr Gewinn | Neuhausen am Rheinfall - Der Medizinalbedarfhersteller IVF Hartmann hat 2024 mehr Umsatz erzielt und mehr verdient. Den Aktionären winkt trotzdem eine tiefere Dividende. Der Umsatz von IVF Hartmann... ► Artikel lesen | |
MODERN DENTAL | 0,472 | +3,06 % | Dividendenbekanntmachungen (03.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEROPORTS DE PARIS SA FR0010340141 - 3 EUR ANHUI CONCH CEMENT CO LTD CNE1000001W2 0,7736 HKD 0,0862 EUR ATMUS FILTRATION TECHNOLOGIES... ► Artikel lesen | |
ICU MEDICAL | 114,00 | -2,56 % | ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America | The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims... ► Artikel lesen | |
XYLO TECHNOLOGIES | 5,060 | 0,00 % | Xylo Technologies Ltd.: Viewbix Shares to Begin Trading on Nasdaq | TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Xylo Technologies Ltd. (Nasdaq: XYLO) ("Xylo" or the "Company"), a technology-based company engaged in advanced innovative technologies, announced... ► Artikel lesen | |
VITRUVIA MEDICAL | 0,510 | 0,00 % | EQS-Adhoc: Vitruvia Medical AG: Jahresergebnis per 31. Dezember 2024 | EQS-Ad-hoc: Vitruvia Medical AG / Schlagwort(e): Jahresergebnis
Vitruvia Medical AG: Jahresergebnis per 31. Dezember 2024
03.05.2025 / 07:57 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
ACADIA HEALTHCARE | 19,700 | 0,00 % | Acadia Healthcare Company, Inc. - S-8, Securities to be offered to employees in employee benefit plans |